What are Vaxcyte, Inc.'s total assets?

Vaxcyte, Inc. (PCVX) holds $3.3B in total assets, down 0.9% year over year.

How much debt does Vaxcyte, Inc. have?

Vaxcyte, Inc. carries $116.3M in total debt against $3.0B of shareholders' equity, a debt-to-equity ratio of 0.04.

How much cash does Vaxcyte, Inc. have?

Vaxcyte, Inc. holds $262.3M in cash and equivalents.

Can Vaxcyte, Inc. cover its short-term obligations?

Its current ratio is 7.49 — current assets exceed current liabilities.

Where does Vaxcyte, Inc.'s balance sheet data come from?

Every line is extracted from Vaxcyte, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Vaxcyte, Inc. PCVX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$262.31M-24.7%	$175.43M-54.9%	$282.55M-73.1%	$308.06M-40.7%	$348.17M-43.2%
Short-term investments	$1.48B+11.4%	$1.39B+2.0%	$1.43B+26.5%	$1.35B+45.0%	$1.32B+51.4%
Restricted cash	$1.47M+11.1%	$1.47M+11.3%	$1.47M+11.4%	$1.32M+19.6%	$1.32M+19.6%
Prepaid expenses and other current assets	$252.91M+71.1%	$221.43M+65.8%	$195.8M+80.5%	$173.36M+65.4%	$147.79M+48.9%
Trading assets	——	——	——	——	——
Total current assets	$1.81B+5.6%	$1.63B-9.0%	$1.77B-20.2%	$1.72B+15.8%	$1.72B+13.1%
Property and equipment, net	$260.7M+20.1%	$257.37M+30.0%	$253.49M+55.3%	$242.27M+92.3%	$217.16M+156%
Operating lease right-of-use assets	7.2%0.0%	7.2%-7,210,199,993%	7.2%-1.1%	7.2%-1.3%	7.2%-1.3%
Other non-current assets	$155.54M+104%	$118.85M+84.7%	$106.71M+77.7%	$95.26M+80.8%	$76.28M+65.3%
Equity method investments	$1B-21.5%	$881.66M-36.5%	$959.26M-12.2%	$1.17B+192%	$1.28B+210%
Available-for-sale securities	——	——	——	——	——
Total noncurrent assets	$1.53B-7.6%	$1.38B-20.2%	$1.4B+4.4%	$1.59B+162%	$1.66B+189%
Total assets	$3.35B-0.9%	$3B-14.5%	$3.17B-10.9%	$3.31B+58.4%	$3.38B+61.5%
Accounts payable	$214.34M+119%	$171.79M+73.8%	$149.34M+130%	$118.6M+89.8%	$97.65M+43.0%
Accrued expenses	$7.99M+33.3%	$23M+11.9%	$16.76M+36.9%	$10.83M+67.6%	$5.99M+93.9%
Operating lease liabilities, current	$6.09M-0.7%	$6.12M+4.0%	$5.77M-40.1%	$6.3M-13.6%	$6.13M-14.9%
Total current liabilities	$242.08M+150%	$205.75M+46.8%	$200.05M+61.6%	$154.49M+86.5%	$97M+11.4%
Operating lease liabilities, non-current	$110.21M+35.9%	$111.46M+70.9%	$78.67M+329%	$79.54M+335%	$81.08M+301%
Operating Lease Liabilities (Total)	$116.3M+33.5%	$117.58M+65.4%	$84.44M+202%	$85.85M+236%	$87.11M+218%
Total liabilities	$352.29M+97.8%	$317.21M+54.4%	$278.72M+96.1%	$234.03M+131%	$178.08M+65.9%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	500M0.0%	500M+390,525%	500M0.0%	500M0.0%	500M0.0%
Additional paid-in capital	$5.48B+15.8%	$4.84B+3.0%	$4.8B+2.8%	$4.77B+52.2%	$4.73B+57.6%
Retained earnings	-$2.48B-61.9%	-$2.15B-55.2%	-$1.91B-52.5%	-$1.7B-47.7%	-$1.53B-50.0%
Accumulated other comprehensive income (loss)	-$6.83M-2,022%	$1.59M+141%	$856K+516%	-$1.89M-204%	-$322K-111%
Total stockholders' equity	$3B-6.4%	$2.69B-18.8%	$2.89B-15.4%	$3.07B+54.6%	$3.2B+61.3%
Total liabilities and stockholders' equity	$3.35B-0.9%	$3B-14.5%	$3.17B-10.9%	$3.31B+58.4%	$3.38B+61.5%
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)	$491.9M—	$120.2M—	$275.9M—	——	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months)	$491.9M—	$120.2M—	$275.9M—	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	——	——	——	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value	$491.9M—	$120.2M—	$275.9M—	——	——
AFS and Trading Securities - Unrealized Loss Position Fair Value	$1.6B—	$300M—	$800M—	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	——	——	——	——	——
Cash, Cash Equivalents, and Marketable Securities	$1.6B+33.3%	$300M-80.0%	$800M—	$1.3B—	$1.2B—
Deferred Tax Assets and Other Non-Current Assets	$155.54M+104%	$118.85M+84.7%	$106.71M+77.7%	$95.26M+80.8%	$76.28M+65.3%
Net Investment in Lease	$113.1M+28.9%	$116.01M+60.9%	$83.52M+191%	$85.65M+220%	$87.76M+204%
Investments	$1B-21.5%	$881.66M-36.5%	$959.26M-12.2%	$1.17B+192%	$1.28B+210%
Operating lease right-of-use assets	$113.1M+28.9%	$116.01M+60.9%	$83.52M+191%	$85.65M+220%	$87.76M+204%
Other non-current assets	$155.54M+104%	$118.85M+84.7%	$106.71M+77.7%	$95.26M+80.8%	$76.28M+65.3%
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$1.48B+11.4%	$1.39B+2.0%	$1.43B+26.5%	$1.35B+45.0%	$1.32B+51.4%
Operating Lease Right-of-Use Assets in Other Assets	$113.1M+28.9%	$116.01M+60.9%	$83.52M+191%	$85.65M+220%	$87.76M+204%
Software and Technology Licenses, Net	$155.54M+104%	$118.85M+84.7%	$106.71M+77.7%	$95.26M+80.8%	$76.28M+65.3%
Accrued Manufacturing Costs	$7.99M+33.3%	$23M+11.9%	$16.76M+36.9%	$10.83M+67.6%	$5.99M+93.9%
Other Commercial Liabilities	$30.25M+16.1%	$31.07M+6.7%	$24.59M-20.0%	$32.21M+45.4%	$26.04M-51.9%
Accrued contract manufacturing expenses	$134.7M—	$74.65M—	$103.96M—	——	——
Accrued Liabilities, Current	$30.25M+16.1%	$31.07M+6.7%	$24.59M-20.0%	$32.21M+45.4%	$26.04M-51.9%
Compensation and benefits	$7.99M+33.3%	$23M+11.9%	$16.76M+36.9%	$10.83M+67.6%	$5.99M+93.9%
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——	——
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——	——
Total debt	$116.3M+33.5%	$117.58M+65.4%	$84.44M+202%	$85.85M+236%	$87.11M+218%
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss	$491.9M—	$120.2M—	$275.9M—	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.00—	$0.00—
Common Stock Shares Issued	144.3M+11.9%	131.1M+4.9%	130M+4.5%	129.8M—	128.9M—
Convertible Preferred Stock Authorized Shares	10M0.0%	10M0.0%	10M0.0%	10M—	10M—
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Additional paid-in capital	$5.48B+15.8%	$4.84B+3.0%	$4.8B+2.8%	$4.77B+52.2%	$4.73B+57.6%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$147K+11.4%	$134K+4.7%	$133K+4.7%	$133K+16.7%	$132K+17.9%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Investments - Gross Unrealized Losses	$1.6B—	$300M—	$800M—	——	——
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.00—	$0.00—
Warrants and Rights Outstanding	——	——	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	——	——	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	——	——	——	——	——
Available for sale investments	——	——	——	——	——
Other Commitment	——	——	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$0—	$0—
Common stock, shares authorized (in shares)	$500M0.0%	$500M0.0%	$500M0.0%	$500M—	$500M—
Common stock, shares issued (in shares)	$144.31M+11.9%	$131.06M+4.9%	$130.03M+4.5%	$129.82M—	$128.94M—
Common Stock, Shares, Outstanding	$144.31M+11.9%	$131.06M+4.9%	$130.03M+4.5%	$129.82M—	$128.94M—
Other Contractual Commitments - Due in Remainder of 2025	——	——	——	——	——
Investments in fair market value, continuous unrealized loss position, less than 12 months and 12 months or longer	——	——	$800K—	——	——
Less than 12 months	——	——	——	——	——
12 months or more	$491.9M—	$120.2M—	$275.9M—	——	——
Debt Securities, Available-for-Sale, Unrealized Loss Position	$1.6B—	$300M—	$800M—	——	——
Lessee Operating Lease Liability Payments Due	——	——	——	——	——
Thereafter	——	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	$0.070.0%	$0.070.0%	$0.07—	$0.07—	$0.07—
Other Commitment	——	——	——	——	——
Thereafter	——	——	——	——	——
Other contractual commitments, Due in 2026 (remainder)	——	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$0—	$0—
Preferred Stock, Shares Authorized	$10M0.0%	$10M0.0%	$10M0.0%	$10M—	$10M—
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—
Purchase Obligation	——	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Vaxcyte, Inc.'s total assets?: Vaxcyte, Inc. (PCVX) holds $3.3B in total assets, down 0.9% year over year.
How much debt does Vaxcyte, Inc. have?: Vaxcyte, Inc. carries $116.3M in total debt against $3.0B of shareholders' equity, a debt-to-equity ratio of 0.04.
How much cash does Vaxcyte, Inc. have?: Vaxcyte, Inc. holds $262.3M in cash and equivalents.
Can Vaxcyte, Inc. cover its short-term obligations?: Its current ratio is 7.49 — current assets exceed current liabilities.
Where does Vaxcyte, Inc.'s balance sheet data come from?: Every line is extracted from Vaxcyte, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.